TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, today announced that it and Royal Philips (“Philips”) have jointly sold a TULSA-PROTM System to University Hospital of Cologne, Germany.
This marks the first sale of a TULSA-PRO System in Germany, and another European sale as a result of the Company’s recent collaboration with Philips, following Profound’s receipt of CE Mark approval in April 2016.
“TULSA-PRO is an innovative, minimally-invasive technique used to treat clinically organ-confined prostate cancer. A prospective clinical trial has been initiated to evaluate the oncologic potential of this type of focal therapy. We look forward to participating in this study and evaluating TULSA-PRO,” said Prof. Dr. Axel Heidenreich, a leading European Urologist and the Director of the Department of Urology at University Hospital of Cologne.
Prof. Dr. David Maintz, Director of the Institute for Diagnostic and Interventional Radiology at University Hospital of Cologne added, “Magnetic Resonance Imaging (“MRI”) is becoming an essential tool in the diagnosis and treatment of prostate cancer. TULSA-PRO is a novel technology that is allowing precise thermal ablation of prostate tissue with millimetre accuracy. We are looking to better understand how this technology could positively impact patients’ quality of life.”
Steve Plymale, Profound Medical CEO, commented, “We are truly delighted with University Hospital of Cologne being the first purchaser of TULSA-PRO in Germany and a key site for our Pivotal Clinical Trial. We are pleased with the expansion of TULSA-PRO adoption in Europe and look forward to making this technology widely available to clinicians and their patients with malignant prostate tissue.”
TULSA-PRO is a unique technology that combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control providing a highly precise prostate treatment tailored to patient-specific anatomy. It has demonstrated accurate and precise ablation of malignant prostate tissue, while providing a favourable safety profile, with low rates of serious or long-term adverse events.
About Profound Medical Corp.
Profound is a Canadian medical device company that developed a unique and minimally invasive procedure to ablate malignant prostate tissue. The Company’s novel technology combines real-time Magnetic Resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. For more information, visit www.profoundmedical.com
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts Media: Rebecca von Goetz Senior Marketing & Communications Specialist Profound Medical Corp. email@example.com T: 647.476.1350, Ext. 426 C: 416.917.8650 Investors: Stephen Kilmer Investor Relations firstname.lastname@example.org T: 647.872.4849
Source:Profound Medical Inc.